AML Therapy With Irradiated Allogeneic Cells | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02105116

AML Therapy With Irradiated Allogeneic Cells
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This pilot clinical trial studies if cells donated by a close genetic relative can help keep acute myeloid leukemia (AML) from coming back after standard chemotherapy induces a complete remission. Blood cells obtained from a donor include a variety of blood cells that may trigger the patient's immune system to react against AML cells.

Status: 
Recruiting
Study Date: 
Sat, 02/01/2014 to Tue, 01/01/2019
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: fludarabine phosphate Given IV Other Names: 2-F-ara-AMP Beneflur Fludara Drug: cytarabine Given IV Other Names: ARA-C arabinofuranosylcytosine arabinosylcytosine Cytosar-U cytosine arabinoside Biological: donor lymphocytes Undergo infusion of donor lymphocytes Other: laboratory biomarker analysis Correlative studies Drug: G-CSF Given IV Other Names: Filgrastim Neupogen®